Management of diabetic foot infections in an era of increasing microbial resistance.
Diabetic foot infections cause substantial morbidity, incur significant costs, and may lead to amputation. Resistant organisms, particularly methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant gram-negative organisms, are becoming more prevalent. Optimal management of diabetic foot infections is multimodal, and includes not only antimicrobial therapy but also biomechanical support and offloading, local wound care, glycemic control, assessment and treatment of underlying vascular disease, and surgical therapy when warranted. Antimicrobial therapy should be targeted at the likely etiologic agents and should take into consideration the depth and severity of infection. With expansion of the reservoir of resistant organisms, obtaining reliable deep cultures can help focus antimicrobial therapy against the dominant pathogens. Newer agents against resistant gram-positive and gram-negative organisms show promise in the treatment of diabetic foot infections.
Nelson
Sandra Bliss
SB
Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, GRJ-504, Boston, MA 02114, USA. sbnelson@partners.org
Diabet Med. 1999 Sep;16(9):767-71
10510954
Clin Infect Dis. 2008 Dec 15;47(12):1537-45
18990064
J Clin Microbiol. 2007 Sep;45(9):2819-28
17609322
Antimicrob Agents Chemother. 2005 Oct;49(10):4368-71
16189124
J Antimicrob Chemother. 2007 Oct;60(4):819-23
17673476
Diabetologia. 2007 Jan;50(1):18-25
17093942
J Antimicrob Chemother. 2004 Oct;54(4):836-9
15375105
Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S145-61
18442163
Diabetes Metab. 2008 Sep;34(4 Pt 1):363-9
18632297
Diabet Med. 2004 Jul;21(7):705-9
15209762
Diabetes Res Clin Pract. 2007 Jan;75(1):47-50
16963148
Antimicrob Agents Chemother. 2006 Aug;50(8):2875-9
16870792
Clin Infect Dis. 2004 Aug 1;39 Suppl 2:S104-14
15306988
Dtsch Med Wochenschr. 2001 Nov 30;126(48):1353-6
11727160
Diabetes Care. 2006 Jun;29(6):1288-93
16732010
N Engl J Med. 2003 Apr 3;348(14):1342-7
12672861
Clin Infect Dis. 2008 Aug 15;47(4):519-27
18611152
Diabet Med. 2004 Jul;21(7):710-5
15209763
Diabetes Care. 2008 Apr;31(4):637-42
18184898
PLoS One. 2008 Oct 03;3(10):e3326
18833331
Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):370-2
18723960
J Chemother. 2006 Dec;18(6):648-51
17267344
J Infect. 2007 May;54(5):439-45
17018235
J Chemother. 2005 Oct;17(5):527-35
16323442
Clin Infect Dis. 2004 Oct 1;39(7):885-910
15472838
Eur J Intern Med. 2005 Dec;16(8):567-70
16314237
Diabet Med. 2003 Feb;20(2):159-61
12581269
JAMA. 2008 Feb 20;299(7):806-13
18285592
Clin Infect Dis. 2006 Jan 1;42(1):57-62
16323092
Diabetes Res Clin Pract. 2008 Jun;80(3):344-51
18291550
Clin Infect Dis. 2004 Aug 1;39 Suppl 2:S115-22
15306989
Int J Low Extrem Wounds. 2006 Sep;5(3):213-6
16928678
Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S66-71
18395871
Clin Infect Dis. 2004 Jun 15;38(12):1673-81
15227611
Diabet Med. 2001 Oct;18(10):822-7
11678973
Clin Infect Dis. 2004 Jan 1;38(1):17-24
14679443
JAMA. 2005 Jan 12;293(2):217-28
15644549
J Antimicrob Chemother. 2005 Feb;55(2):240-5
15659542
Clin Microbiol Infect. 2006 Feb;12(2):186-9
16441460
Diabetes Care. 2007 Feb;30(2):270-4
17259493
Antimicrob Agents Chemother. 2006 Nov;50(11):3959-62
16982780
Clin Microbiol Infect. 2007 Apr;13(4):351-3
17359317
Lancet. 2005 Nov 12;366(9498):1695-703
16291062
Clin Infect Dis. 2009 Apr 1;48(7):888-93
19228109
Diabet Med. 2004 Sep;21 Suppl 4:16-9
15315521